Patent ID: 11906532
Assignee: HAEMONETICS CORPORATION
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 3:
4. A method of preparing a formulation for testing an efficacy of at least one viscoelastic analysis reagent, the formulation having a target concentration of bovine citrated plasma, a target concentration of human tissue factor, and a target concentration of heparin, the method comprising:
a) determining the target concentration of bovine citrated plasma for the formulation by:
i) measuring a first viscoelastic characteristic for a bovine citrated plasma dilution to obtain a first value for the bovine citrated plasma dilution, said first viscoelastic characteristic having a target value, and
ii) determining a predicted bovine citrated plasma concentration based on the first value and corresponding to the first viscoelastic characteristic target value, the predicted bovine citrated plasma concentration being the target bovine citrated plasma concentration;

b) determining the target concentration of human tissue factor for the formulation by:
i) measuring a second viscoelastic characteristic for a human tissue factor dilution to obtain a second value for the human tissue factor dilution, said second viscoelastic characteristic having a target value, and
ii) determining a predicted human tissue factor concentration based on the second value and corresponding to the second viscoelastic characteristic target value, the predicted human tissue factor concentration being the target human tissue factor concentration;

c) determining the target concentration of heparin for the formulation by:
i) measuring a third viscoelastic characteristic for a heparin dilution to obtain a third value for the heparin dilution, said third viscoelastic characteristic having a target value, and
ii) determining a predicted heparin concentration based on the third value and corresponding to the third viscoelastic characteristic target value, the predicted heparin concentration being the target heparin concentration; and

d) preparing the formulation by combining the bovine citrated plasma, the human tissue factor, and the heparin together such that the formulation comprises the bovine citrated plasma at the target bovine citrated plasma concentration, the human tissue factor at the target human tissue factor concentration, the heparin at the target heparin concentration.